Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axitinib intravitreal implant - Ocular Therapeutix

Next Previous
Drug Profile

Axitinib intravitreal implant - Ocular Therapeutix

Alternative Names: AXPAXLI; OTX-TKI; Tyrosine kinase inhibitor implant

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ocular Therapeutix
  • Class Antineoplastics; Benzamides; Eye disorder therapies; Imidazoles; Indazoles; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase I Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion

Most Recent Events

  • 25 Jan 2024 US FDA agrees to amend a Special Protocol Assessment (SPA) for the phase III SOL trial for the treatment of Wet age-related macular degeneration
  • 18 Dec 2023 Ocular Therapeutix completes the phase I trial in Wet age-related macular degeneration in USA (Intravitreous) (NCT04989699)
  • 03 Oct 2023 Phase-III clinical trials in Wet age-related macular degeneration (Treatment-naive) in USA (Intravitreous) (NCT06223958)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top